Clinical trials on the mutant KRAS-targeted long peptide vaccine for high-risk pancreatic cancer recipients and EGFR-targeted vaccine for high-risk lung cancer recipients are currently underway (NCT05013216, NCT04298606). Here, KRAS is linked to lung cancer.